PMV Pharma Q2 net loss widens on higher R&D expenses

Pmv Pharmaceuticals

07/08/2025 13:50

Overview

PMV Pharma reports Q2 net loss of $21.2 mln, up from $1.2 mln in 2024

R&D expenses rise to $18.4 mln due to rezatapopt program costs

Cash reserves of $148.3 mln expected to last until end of 2026

Outlook

Company expects cash runway to end of 2026

Result Drivers

R&D EXPENSES - Increase to $18.4 mln driven by rezatapopt program costs

G&A EXPENSES - Decrease due to reduced stock-based compensation and operational costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.41
Q2 Net Income
-$21.21 mln
Q2 Operating Expenses
$22.88 mln
Q2 Operating Income
-$22.88 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $6.00, about 74.7% above its August 6 closing price of $1.52

Press Release: ID:nGNXbkvvdm

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)